



A Pilot Plant for the Production of Polymer-based Nanopharmaceuticals in Compliance with GMP – www.nanopilot.eu


NanoPilot is a four-year (2015 – 2018) project coordinated by IK4-CIDETEC, aiming to **set-up a pilot plant operating under Good Manufacturing Practice (GMP) for the production of polymer-based nanopharmaceuticals**. This pilot plant is expected to accelerate the development of nanomedicine in Europe, currently still in its infancy within the pharmaceutical sector.

The Nanomedicine ETP has recorded **more than 700 European companies working in the field of nanomedicine**. There is **high potential of innovation**, however the production of innovative nanopharmaceuticals in quantity and quality (GMP) required for them to **enter clinical trials remains a challenge**. In this context, it is needed to **provide SMEs and research groups with the tools that can help them with the development of their nanopharmaceuticals**.

During the project, **siRNA-based nanopharmaceuticals, HIV nanovaccine and hyaluronan-based spheres** will be produced at the pilot plant. State of the art production processes including micro reactors and highly advanced characterization techniques will ensure the quality of the nanodrugs. At the end of the project (around 2017-2018) the aim is to expand the pilot plant offering also to other users and other kinds of (polymeric) nanopharmaceuticals.

Nanopilot will offer:

- ✓ Small GMP batches for clinical trials
- ✓ Flexibility and adaptability
- ✓ Regulatory compliance



Currently, our goal is to find out the **requirements, needs and views of potential future users** of the NanoPilot plant in order to design the service to fit the customers' needs in the best possible way.

